A. Salmen

Type de document

Articles (11) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Multiple sclerosis (9) maladie (7) âge (7) Swiss (7) Age (7) Age (7) maladie (7) Diagnosis (6) Persons (6) Patients (6) Diagnosis (6) Patients (6) analyse (5) Human beings (5) Analysis (5) temps (durée) (4) Treatment (4) Time (4) Disabilities (4) Value (3) Symptoms (3) Sex (3) Regression analysis (3) Influence (3) Models (3) Imaging (3) cohorte (3) puits (2) logiciel (2) risque (2)

Documents écrit par A. Salmen (11) | parle de A. Salmen (0)

Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
J. Oechtering et al.
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
A. Cagol et al. (9 janv. 2024)
A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients.
A.R. Todea et al.
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.
B.C. Özdemir et al.
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients.
B.C. Özdemir et al.
The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing.
D. Chiavi et al. (10 nov. 2022)
Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry.
M. Stanikić et al.
Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
J. Oechtering et al.
How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
L. Barin et al.
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
M. Kaufmann et al. (2020)
Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.
M. Kaufmann et al. (2018)